Study of Tazarotene in Advanced Cancer Patients
Author Information
Author(s): Jones P H, Burnett R D, Fainaru I, Nadolny P, Walker P, Yu Z, Tang-Liu D, Ganesan T S, Talbot D C, Harris A L, Rustin G J S
Primary Institution: MRC Cancer Cell Unit and Cancer Research UK Department of Oncology, University of Cambridge
Hypothesis
Does tazarotene have an acceptable safety profile and maximum tolerated dose when administered to patients with advanced cancer?
Conclusion
Tazarotene is well tolerated in cancer patients at a maximum tolerated dose of 25.2 mg per day over 12 weeks.
Supporting Evidence
- Tazarotene was administered to 34 patients with advanced cancer.
- The maximum tolerated dose was determined to be 25.2 mg per day.
- Adverse events were reported in 30 out of 34 patients.
- Nine patients showed stable disease after 12 weeks of treatment.
Takeaway
This study tested a new cancer drug called tazarotene to see if it is safe for patients with advanced cancer. It found that the drug can be taken safely at a certain dose.
Methodology
Patients with advanced cancer were given tazarotene for 12 weeks to assess safety and maximum tolerated dose.
Potential Biases
Potential bias due to lack of randomization and small patient numbers.
Limitations
The study had a small sample size and lacked a control group.
Participant Demographics
{"mean_age":58.5,"age_range":"39-72","gender_distribution":{"male":20,"female":14},"ethnicity":"Caucasian"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website